Intellia offering
Nettet2. jul. 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the closing of an underwritten public offering of … NettetBased on 14 analysts offering 12 month price targets for Intellia Therapeutics Inc. Min Forecast. $39.00 +8.45%. Avg Forecast. $79.64 +121.48%. Max Forecast. $120.00 +233.7%. ... The average Intellia Therapeutics stock price prediction forecasts a potential upside of 121.48% from the current NTLA share price of $35.96.
Intellia offering
Did you know?
Nettet2. jul. 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … Nettet28. jun. 2024 · CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company …
Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … Nettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of …
Nettet30. nov. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public offering …
Nettet30. jun. 2024 · CAMBRIDGE, Mass., June 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company …
NettetCAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative … gate hospitality group logoNettet30. nov. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company … davis and campbell funeral home nashville tnNettet28. jun. 2024 · Intellia is developing NTLA-2001 with Regeneron Pharmaceutical under a collaboration that began in 2016. The deal calls for the partners to develop CRISPR-based therapies that target the liver... gate hospitality jobsNettet1. des. 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of … gate hospitality groupNettet2. des. 2024 · CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on … davis and byers venice flNettet30. nov. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based … gate hospitality jacksonville flNettet1. des. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based … davis and chacon beating the ufw